Rubric Capital Management LP boosted its position in Arcutis Biotherapeutics by 27.6% during the first quarter. now owns 5,081,744 shares of the company’s stock valued at $97,110,000 after purchasing an additional 503,591 shares in the last quarter. boosted its position in Arcutis Biotherapeutics by 11.0% during the third quarter. FMR LLC now owns 9,162,430 shares of the company’s stock valued at $100,787,000 after acquiring an additional 23,257 shares in the last quarter. FMR LLC boosted its position in Arcutis Biotherapeutics by 0.3% during the 1st quarter. Hedge funds and other institutional investors have recently modified their holdings of the business. Hedge Funds Weigh In On Arcutis Biotherapeutics 20.70% of the stock is owned by corporate insiders. Insiders sold 18,830 shares of company stock worth $235,104 in the last 90 days. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Following the transaction, the director now directly owns 165,825 shares in the company, valued at approximately $2,316,575.25. The shares were sold at an average price of $13.97, for a total value of $118,745.00. Welgus sold 8,500 shares of the company’s stock in a transaction dated Monday, April 17th. In other Arcutis Biotherapeutics news, Director Howard G. Insider Activity at Arcutis Biotherapeutics will post -4.95 EPS for the current year. As a group, sell-side analysts expect that Arcutis Biotherapeutics, Inc. The business had revenue of $2.78 million during the quarter, compared to analyst estimates of $3.50 million. The company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.01).
ARQ WEALTH ADVISORS FREE
Get Arcutis Biotherapeutics alerts:Īrcutis Biotherapeutics ( NASDAQ:ARQT – Free Report) last released its earnings results on Tuesday, May 9th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $45.33. Finally, Needham & Company LLC restated a “buy” rating and set a $24.00 price objective on shares of Arcutis Biotherapeutics in a research report on Wednesday, April 19th. Truist Financial dropped their price target on Arcutis Biotherapeutics from $45.00 to $40.00 in a research report on Friday, May 26th. 500.com restated a “reiterates” rating on shares of Arcutis Biotherapeutics in a research report on Monday, June 12th. Mizuho dropped their price objective on shares of Arcutis Biotherapeutics from $61.00 to $57.00 in a research note on Wednesday, May 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcutis Biotherapeutics in a report on Wednesday, March 1st. Several analysts have recently issued reports on the company. The stock had previously closed at $8.55. 67,135 shares changed hands during mid-day trading, a decline of 94% from the average session volume of 1,128,535 shares. The stock traded as low as $8.11 and last traded at $8.20. ( NASDAQ:ARQT – Free Report) traded down 4.1% during mid-day trading on Tuesday.
0 kommentar(er)
